Retatrutide (research code LY3437943), nicknamed R3, Reta or GLP-3, is a peptide developed by Eli Lilly. It activates three hormone receptors at once: the GIP, GLP-1 and glucagon receptors. This vial contains 20 mg of lyophilized retatrutide, twice as much as the 10 mg vial, with four published, verifiable Janoshik analyses.
At a glance
- Product: 1 vial of 20 mg retatrutide, lyophilized powder.
- Vial price: €99.90 per vial, or €5.00 per mg.
- Molecule: triple GIP, GLP-1 and glucagon receptor agonist, modified with a fatty acid.
- Analyses: 4 Janoshik reports on 3 batches, HPLC purity from 99.446 to 99.902%, 22.76 to 23.40 mg measured per vial.
- Verification: each report has a number and a key, to enter on the laboratory's website.
- Shipping: 2 to 5 business days from France, €10 delivery, free from €160.
- Intended use: scientific laboratory research only.
Our 4 Janoshik analyses of retatrutide 20 mg
| Date | Declared batch | HPLC purity | Measured quantity | Report and key |
|---|---|---|---|---|
| 14/10/2026 | MP-777RT202 | 99,446 % | 22.78 mg | #241204 · GBVZ8XEY3THI |
| 01/09/2026 | MP-777RT201 | 99,852 % | 23.33 mg | #226146 · S4JYCX1DK2PT |
| 25/08/2026 | MP-777RT201 | 99,902 % | 22.76 mg | #223435 · HYUP43B55P3Z |
| 05/08/2026 | 777521 | 99,778 % | 23.40 mg | #214175 · H4W5LK6XR35W |
All four vials analyzed contain more than the stated 20 mg. Batch MP-777RT201 was analyzed twice, one week apart, with similar results.
What these reports do not say: the batch and the manufacturer are entered by whoever orders the analysis, so they are declarations. The analyses measure purity and quantity. They do not cover sterility, endotoxins or heavy metals.
Retatrutide 20 mg or 10 mg?
It is the same molecule. The 20 mg vial contains twice as much powder and costs less per mg.
| Format | Price | Price per mg |
|---|---|---|
| 10 mg vial | €59.90 | €5.99 |
| 20 mg vial | €99.90 | €5.00 |
| Pack R20: 20 mg vial and reconstitution kit | €109.90 | – |
| Pack of 3 vials of 20 mg (60 mg) | €270.00 | €4.50 |
- Retatrutide 10 mg
- Pack R20: retatrutide 20 mg and reconstitution kit
- Retatrutide 60 mg: pack of 3 vials of 20 mg
- Retatrutide prices in Europe
Status: not an approved medicine
Retatrutide does not have marketing authorization anywhere, either in Europe or in the United States. In 2026, Eli Lilly published the results of its first phase 3 trials, and it plans to file its application with the US Food and Drug Administration (FDA) in the first quarter of 2027. No submission to the European Medicines Agency has been announced.
The vial sold here is therefore not a medicine: it is a lyophilized research peptide, for laboratory use only.
Mechanism of action
Retatrutide mimics three hormones. Through the GLP-1 receptor, it reduces appetite, slows gastric emptying and stimulates insulin secretion when blood glucose rises. Through the GIP receptor, it enhances insulin secretion. Through the glucagon receptor, it increases energy expenditure and drives the liver to use its fat stores.
Its action is not symmetrical: in the laboratory, it acts more strongly on the GIP receptor than on the GLP-1 and glucagon receptors. In obese mice, the increase in energy expenditure driven by glucagon adds to the reduction in calorie intake driven by GIP and GLP-1 (Coskun, 2022).
A fatty acid chain allows it to bind to albumin in the blood. Its half-life, measured in a clinical trial, is about 6 days (Urva, 2022).
What the clinical trials show
- Phase 2, obesity: 338 adults followed for 48 weeks. Mean weight loss of 8.7 to 24.2% depending on the group, versus 2.1% with placebo (Jastreboff, 2023).
- TRIUMPH-1, phase 3, obesity: 2,339 adults without diabetes followed for 80 weeks. Mean weight loss of 17.6 to 25.0% depending on the group, versus 3.9% with placebo. Knee pain in participants with osteoarthritis and the number of apnea episodes in participants with sleep apnea fell more than with placebo (Jastreboff, 2026).
- TRIUMPH-2, obesity and type 2 diabetes: 1,152 adults followed for 80 weeks. Mean weight loss of 11.9 to 18.8% depending on the group, versus 5.1% with placebo (Bellido, 2026).
- TRANSCEND-T2D-1, type 2 diabetes: 537 adults followed for 40 weeks. HbA1c reduction of 1.69 to 1.94 percentage points depending on the group, versus 0.81 with placebo, and weight loss of 11.5 to 15.3% (Bajaj, 2026).
- Liver fat: in 98 participants with fatty liver disease (steatosis), liver fat fell by 42.9 to 82.4% over 24 weeks depending on the group, versus a 0.3% increase with placebo (Sanyal, 2024).
- Adverse effects: mainly gastrointestinal, in particular diarrhea and nausea, more frequent than with placebo. In TRIUMPH-2, 4 to 12% of participants stopped treatment because of an adverse effect, versus 5% with placebo (Bellido, 2026).
For TRIUMPH-1, Eli Lilly had announced 28.3% weight loss, counting only the participants who stayed on treatment. The publication reports 25.0%, counting all participants.
These results concern the medicine in development, in supervised trials. They do not describe a research peptide.
Retatrutide, tirzepatide or semaglutide?
| Molecule | Receptors | Status | Published weight loss |
|---|---|---|---|
| Semaglutide | GLP-1 | Approved as a medicine (Ozempic, Wegovy) | 14.9% in 68 weeks (STEP 1) |
| Tirzepatide | GIP and GLP-1 | Approved as a medicine (Mounjaro, Zepbound) | Up to 20.9% in 72 weeks (SURMOUNT-1) |
| Retatrutide | GIP, GLP-1 and glucagon | Not approved, FDA filing planned for 2027 | Up to 25.0% in 80 weeks (TRIUMPH-1) |
These figures come from different trials, run in different populations and over different durations: the comparison remains indirect.
- Retatrutide, tirzepatide or semaglutide: the comparison
- Tirzepatide 10 mg
- Retatrutide or cagrilintide: the differences
- GLP-3: why the nickname?
Technical specifications
| Molecule | Retatrutide, LY3437943 |
|---|---|
| Type | Peptide modified with a fatty acid, triple GIP, GLP-1 and glucagon agonist |
| Molecular formula | C₂₂₁H₃₄₂N₄₆O₆₈ |
| Molecular weight | About 4,731 g/mol |
| Quantity per vial | 20 mg |
| Form | Lyophilized powder |
| Analyses | 4 Janoshik reports, HPLC purity from 99.446 to 99.902% |
| Storage | -20 °C before reconstitution |
Reconstitution and storage
Retatrutide is reconstituted with bacteriostatic water (0.9% benzyl alcohol). Let the water run down the inside wall of the vial, then swirl gently, without shaking. The volume of water sets the concentration: with 2 mL, the solution contains 10 mg per mL.
Before reconstitution, store the vial at -20 °C. After reconstitution, keep the solution between 2 and 8 °C and use it within 4 weeks. Avoid repeated freezing and thawing.
- Reconstitution Pack: bacteriostatic water, syringes, gloves and swabs, €14.90
- Bacteriostatic water 3 ml, €5
- Reconstitution calculator
Retatrutide 20 mg price
The 20 mg vial costs €99.90, or €5.00 per mg. In a pack of 3 vials, the 60 mg cost €270, or €4.50 per mg, and delivery is free. Delivery is €10 for a single vial, free from €160.
Shipping
Discreet packaging and shipping from France in 2 to 5 business days to the EU countries we serve. Overseas territories and Norway: longer lead time.
Secure payment by credit card, Apple Pay or Google Pay.
MyPeptide is a European shop based in Paris. This product is intended exclusively for scientific research.
Frequently asked questions about retatrutide 20 mg
What is retatrutide?
Retatrutide (LY3437943) is a peptide developed by Eli Lilly that activates the GIP, GLP-1 and glucagon receptors at the same time. It is the first triple agonist of this kind to have reached phase 3 clinical trials.
Why is it called R3 or GLP-3?
R3 and Reta are abbreviations of retatrutide. GLP-3 is a nickname that refers to its three targets: it is not the name of a hormone. The official name remains retatrutide, and Eli Lilly's research code is LY3437943.
What is the difference between retatrutide 20 mg and 10 mg?
It is the same molecule. The 20 mg vial contains twice as much powder and costs less: €5.00 per mg, versus €5.99 per mg for the 10 mg vial.
Is retatrutide an approved medicine?
No. It does not have marketing authorization anywhere. Eli Lilly plans to file its application with the FDA in the first quarter of 2027, and no application has been announced in Europe. Our vial is a research peptide, for laboratory use only.
What do the phase 3 trials show?
In TRIUMPH-1, published in 2026, 2,339 adults without diabetes lost on average 17.6 to 25.0% of their body weight over 80 weeks depending on the group, versus 3.9% with placebo. The most common adverse effects were gastrointestinal.
What is the difference between retatrutide and tirzepatide?
Tirzepatide activates the GIP and GLP-1 receptors. Retatrutide also activates the glucagon receptor, which increases energy expenditure. Tirzepatide is an approved medicine; retatrutide is not yet.
Do you have analysis reports for retatrutide 20 mg?
Yes, four Janoshik reports on three batches, with an HPLC purity of 99.446 to 99.902% and 22.76 to 23.40 mg measured per vial. Each report has a number and a key, which you can verify on the laboratory's website.
What does the vial contain?
20 mg of lyophilized retatrutide, in powder form. The vial contains no solvent: bacteriostatic water is sold separately or in the Reconstitution Pack.
How should retatrutide be reconstituted and stored?
With bacteriostatic water, added slowly down the inside wall, without shaking. Before reconstitution, store the vial at -20 °C; afterwards, keep the solution between 2 and 8 °C and use it within 4 weeks.
How much does retatrutide 20 mg cost?
€99.90 for the 20 mg vial, or €5.00 per mg. The pack of 3 vials of 20 mg costs €270, or €4.50 per mg, with free delivery.
How long does delivery take?
We ship in 2 to 5 business days to the EU countries we serve. Delivery costs €10 and is free from €160.
Sources
- Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism, 2022.
- Urva S et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multiple-ascending dose trial. The Lancet, 2022.
- Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity, a phase 2 trial. New England Journal of Medicine, 2023.
- Sanyal AJ et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine, 2024.
- Bajaj HS et al. Efficacy and safety of retatrutide in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a phase 3 trial. The Lancet, 2026.
- Jastreboff AM et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity (TRIUMPH-1). New England Journal of Medicine, 2026.
- Bellido V et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a phase 3 trial. The Lancet, 2026.
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022.
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021.





Lobna JARJIR –
Anonyme –
Great product, I highly recommend it!
Stephen –
Fast Delivery. Good Product